Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study - PubMed
3 hours ago
- #chronic kidney disease
- #dapagliflozin
- #finerenone
- Combination therapy of finerenone and dapagliflozin shows superior efficacy in reducing urinary albumin-to-creatinine ratio (UACR) compared to dapagliflozin alone in non-diabetic CKD patients.
- The combination therapy also better preserves or improves estimated glomerular filtration rate (eGFR) over a 6-month period.
- Mediation analysis suggests that the benefits of combination therapy on eGFR are largely independent of albuminuria reduction.
- Safety profiles between combination therapy and monotherapy were similar, with manageable adverse events.
- The study provides real-world evidence supporting the additive renoprotective effects of finerenone and dapagliflozin in non-diabetic CKD.